Literature DB >> 1324272

Central mu-opioid receptors are down-regulated in a rat model of cholestasis.

N V Bergasa1, R B Rothman, J Vergalla, H Xu, M G Swain, E A Jones.   

Abstract

Ameliorations of the pruritus of cholestasis by opioid antagonists are consistent with this form of pruritus being centrally mediated by the opioid system. To determine whether the central opioid system is altered in cholestasis, the specific binding of a selective mu-opioid receptor ligand, 3H-DAMGO, to mu-opioid receptors was studied in rats with acute cholestasis due to bile duct resection. Using whole brain membranes and subcellular mitochondrial-synaptosomal fractions the density of mu-receptor sites was 30% (p less than 0.01) and 22% (p = 0.03) less in bile-duct-resected rats than in sham-resected rats. Using membranes from individual brain regions specific binding of 3H-DAMGO was reduced by 43-53% in the cerebral cortex, hippocampus and caudate nucleus of bile-duct-resected rats. Thus mu-opioid receptors in the brain are down-regulated in a classical model of cholestasis. This alteration of the central opioid system could be a consequence of increased exposure of opioid receptors to endogenous opioids in cholestasis and may reflect an important mechanism in the pathogenesis of the pruritus of cholestasis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324272     DOI: 10.1016/0168-8278(92)90040-v

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

Review 1.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 2.  Jaundice associated pruritis: a review of pathophysiology and treatment.

Authors:  Ramez Bassari; Jonathan B Koea
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Why do cholestatic patients itch?

Authors:  E A Jones; N V Bergasa
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

4.  micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.

Authors:  Dania Chakass; David Philippe; Edmone Erdual; Sébastien Dharancy; Mathilde Malapel; Caroline Dubuquoy; Xavier Thuru; Jerome Gay; Claire Gaveriaux-Ruff; Pierre Dubus; Philippe Mathurin; Brigitte L Kieffer; Pierre Desreumaux; Mathias Chamaillard
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

5.  Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Authors:  Saadet Inan; Alan Cowan
Journal:  Handb Exp Pharmacol       Date:  2022

6.  The TGR5 receptor mediates bile acid-induced itch and analgesia.

Authors:  Farzad Alemi; Edwin Kwon; Daniel P Poole; TinaMarie Lieu; Victoria Lyo; Fiore Cattaruzza; Ferda Cevikbas; Martin Steinhoff; Romina Nassini; Serena Materazzi; Raquel Guerrero-Alba; Eduardo Valdez-Morales; Graeme S Cottrell; Kristina Schoonjans; Pierangelo Geppetti; Stephen J Vanner; Nigel W Bunnett; Carlos U Corvera
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

Review 7.  Pruritus in chronic liver disease: mechanisms and treatment.

Authors:  Nora V Bergasa
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 8.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides.

Authors:  Marco Marzioni; Giammarco Fava; Domenico Alvaro; Gianfranco Alpini; Antonio Benedetti
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.